These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 31090367)

  • 1. Pulmonary arterial hypertension in Russia: six-year observation analysis of the National Registry.
    Chazova IE; Arkhipova OA; Martynyuk TV
    Ter Arkh; 2019 Mar; 91(1):24-31. PubMed ID: 31090367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Instrumental Characteristics of Newly Diagnosed Patients with Various Forms of Pulmonary Hypertension according to the Russian National Registry.
    Chazova IY; Martynyuk TV; Valieva ZS; Gratsianskaya SY; Aleevskaya AM; Zorin AV; Nakonechnikov SN
    Biomed Res Int; 2020; 2020():6836973. PubMed ID: 32626754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pulmonary arterial hypertension in patients with congenital heart disease: current issues and health care situation].
    Kaemmerer H; Gorenflo M; Hoeper M; Huscher D; Ewert P; Pittrow D
    Dtsch Med Wochenschr; 2013 Jun; 138(23):1247-52. PubMed ID: 23720182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline Characteristics of the Korean Registry of Pulmonary Arterial Hypertension.
    Chung WJ; Park YB; Jeon CH; Jung JW; Ko KP; Choi SJ; Seo HS; Lee JS; Jung HO;
    J Korean Med Sci; 2015 Oct; 30(10):1429-38. PubMed ID: 26425039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Bosentan Patient Registry: long-term survival in pulmonary arterial hypertension.
    Keogh A; Strange G; McNeil K; Williams TJ; Gabbay E; Proudman S; Weintraub RG; Wlodarczyk J; Dalton B
    Intern Med J; 2011 Mar; 41(3):227-34. PubMed ID: 20002851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry).
    Barst RJ; Ivy DD; Foreman AJ; McGoon MD; Rosenzweig EB
    Am J Cardiol; 2014 Jan; 113(1):147-55. PubMed ID: 24176071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic Evaluation of Children with Persistent or Recurrent Pulmonary Arterial Hypertension Following Complete Repair of Congenital Heart Disease.
    Latus H; Wagner I; Ostermayer S; Kerst G; Kreuder J; Schranz D; Apitz C
    Pediatr Cardiol; 2017 Oct; 38(7):1342-1349. PubMed ID: 28681131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of high risk factors for patient death and its clinical characteristics on pregnancy associated with pulmonary arterial hypertension].
    Bao Z; Zhang J; Yang D; Xu X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):495-500. PubMed ID: 25327730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A binational registry of adults with pulmonary arterial hypertension complicating congenital heart disease.
    Strange G; Rose M; Kermeen F; O'Donnell C; Keogh A; Kotlyar E; Grigg L; Bullock A; Disney P; Dwyer N; Whitford H; Tanous D; Frampton C; Weintraub R; Celermajer DS
    Intern Med J; 2015 Sep; 45(9):944-50. PubMed ID: 26011062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease.
    Baptista R; Castro G; da Silva AM; Monteiro P; Providência LA
    Rev Port Cardiol; 2013 Feb; 32(2):123-9. PubMed ID: 23351920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report.
    Keogh A; Strange G; Kotlyar E; Williams T; Kilpatrick D; Macdonald P; Brown K; Pidoux A; Kermeen F; Steele P; Dalton B; Gabbay E
    Intern Med J; 2011 Mar; 41(3):235-44. PubMed ID: 21118410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pulmonary hypertension in Russia: the first results of the national register].
    Chazova IE; Arkhipova OA; Valieva ZS; Nakonechnikov SN; Martyniuk TV
    Ter Arkh; 2014; 86(9):56-64. PubMed ID: 25518507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry.
    Barst RJ; Chung L; Zamanian RT; Turner M; McGoon MD
    Chest; 2013 Jul; 144(1):160-168. PubMed ID: 23429998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
    Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.
    Humbert M; Coghlan JG; Ghofrani HA; Grimminger F; He JG; Riemekasten G; Vizza CD; Boeckenhoff A; Meier C; de Oliveira Pena J; Denton CP
    Ann Rheum Dis; 2017 Feb; 76(2):422-426. PubMed ID: 27457511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension.
    Kylhammar D; Persson L; Hesselstrand R; Rådegran G
    Scand Cardiovasc J; 2014 Aug; 48(4):223-33. PubMed ID: 24912571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
    Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
    Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.
    Rhee RL; Gabler NB; Sangani S; Praestgaard A; Merkel PA; Kawut SM
    Am J Respir Crit Care Med; 2015 Nov; 192(9):1111-7. PubMed ID: 26291092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.